# A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

> **NCT06263231** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Intensity Therapeutics, Inc.** · enrollment: 333 (estimated)

## Conditions studied

- Sarcoma,Soft Tissue

## Interventions

- **DRUG:** INT230-6
- **DRUG:** Eribulin
- **DRUG:** Trabectedin
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT06263231
- **Lead sponsor:** Intensity Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 333 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263231, "A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06263231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*